SBMFF.PK

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

Retrieved on: 
星期二, 八月 23, 2022
Russell Midcap Index, Hang Seng Composite Index Series, Hong, Hang Seng Index, Safety, Research, Hang Seng China Enterprises Index, Pulmonary fibrosis, Sino Biopharmaceutical Limited, Interim, Board, Hepatitis, ROCK2, Respiratory system, Medullary thyroid cancer, Liver disease, Flurbiprofen, III, Thyroid cancer, Clinical trial, Forbes, Growth, Analgesic, Marketing, Patient, Board of directors, Fine chemical, Pharmaceutical industry, Pneumoconiosis, Group, PRC

-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.

Key Points: 
  • -- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.
  • During the Period, the Group recorded revenue of approximately RMB15.19 billion, an increase of approximately 5.9% against last year.
  • Sales of oncology medicines increased by 16.7% year-on-year to approximately 4.96 billion, accounting for approximately 32.6% of the Group's revenue.
  • Sino Biopharmaceutical Limited is a leading, innovative R&D-driven pharmaceutical conglomerate in the PRC.